![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1793599
¼¼°èÀÇ Ã¼¿Ü Áø´Ü(IVD) ½Ã¾à ½ÃÀå : ½ÃÀå ±Ô¸ð ºÐ¼®(À¯Çüº°, ±â¼úº°, ¿ëµµº°, ÃÖÁ¾ »ç¿ëÀÚº°, Áö¿ªº°)°ú ¿¹Ãø(2025-2035³â)Global IVD Reagents Market Size Study & Forecast, by Type, Technology, Application, End-User and Regional Forecasts 2025-2035 |
¼¼°èÀÇ Ã¼¿Ü Áø´Ü(IVD) ½Ã¾à ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ ¾à 807¾ï 2,000¸¸ ´Þ·¯°¡ µÇ¾úÀ¸¸ç, 2025³âºÎÅÍ 2035³â±îÁöÀÇ ¿¹Ãø ±â°£¿¡ ÀÖ¾î¼ CAGR 6.80% ÀÌ»óÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.
ü¿ÜÁø´Ü¿ë(IVD) ½Ã¾àÀº ÀÇ·áÁø´Ü¿¡ ÇʼöÀûÀÎ ±¸¼º¿ä¼Ò·Î, ÀÓ»óÀÇ¿Í °Ë»ç½ÇÀÌ Á¤È®Çϰí Á¶±â¿¡ Áúº´ ƯÀÌÀûÀÎ °Ë»ç¸¦ ½Ç½ÃÇÒ ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ½Ã¾àÀº ü¿Ü Áø´Ü(IVD) ½Ã¾à ¹× ŰƮ¿Í Á¶ÇÕÇÏ¿© »ç¿ëµÇ¾î °¨¿°Áõ, ¸¸¼º Áúȯ, À¯ÀüÀû ¼ÒÀÎÀ» ƯÁ¤Çϰí, ÀÇ·á Á¦°ø¾÷üÀÇ ÀÇ»ç °áÁ¤ ÇÁ·Î¼¼½º¸¦ ´ëÆø °¡¼Ó½Ãŵ´Ï´Ù. ¼¼°èÀÇ ³ëÈ¿Í È¯ÀÚÀÇ ÀÇ½Ä Áõ°¡¿Í ´õºÒ¾î ¸¸¼º Áúȯ°ú °¨¿°ÀÇ ±ÞÁõÀº Á¤±³ÇÏ°í ½Å¼ÓÇÑ Áø´Ü ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ µÞ¹ÞħÇÏ°í ¼¼°èÀÇ Ã¼¿Ü Áø´Ü(IVD) ½Ã¾à ½ÃÀå ¼ºÀåÀÇ ±âÆøÁ¦°¡µÇ°í ÀÖ½À´Ï´Ù.
ÀÚµ¿È, ³ôÀº 󸮷® °Ë»ç, Áø´Ü ÀåºñÀÇ ¼ÒÇüÈ µî Áø´Ü ±â¼úÀÇ Áøº¸µµ ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, COVID-19 ÆÒµ¥¹Í Áß ¹× ÆÒµ¥¹Í ÈÄ ºÐÀÚÁø´Ü ±â¼úÀÇ Àü°³°¡ Áõ°¡ÇÔ¿¡ µû¶ó È®Àå °¡´ÉÇϰí È¿À²ÀûÀÎ ½Ã¾à Á¦Á¦ÀÇ Çʿ伺ÀÌ °Á¶µË´Ï´Ù. °Ô´Ù°¡, °³ÀÎÈµÈ ÀÇ·áÀÇ ±ÞÁõ°ú À¯ÀüüÇÐ ¹× ¹ÙÀÌ¿À¸¶Ä¿ ¿¬±¸¿¡ ´ëÇÑ ÅõÀÚ°¡ Áõ°¡ÇÔ¿¡ µû¶ó, ½Ã¾àÀº ÀÇ·á Áø´Ü¿¡¼ Çõ½ÅÀÇ Áø¿øÁö¿¡ ÀÚ¸®Àâ°í ÀÖ½À´Ï´Ù. ±×·¯³ª ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎÀÌ ¾ø´Â °ÍÀº ¾Æ´Ï°í, °íµµÀÇ ½Ã¾àÀ̳ª ±â±â¿Í °ü·ÃµÈ °íºñ¿ë, ¾ö°ÝÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©, »óȯÀÇ Á¦ÇÑ µîÀÌ ±Þ¼ÓÇÑ È®´ë¿¡ ÀÖ¾î¼ °úÁ¦°¡ µÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2024³â ¼¼°èÀÇ Ã¼¿Ü Áø´Ü(IVD) ½Ã¾à ½ÃÀå¿¡¼ ¾ÐµµÀûÀÎ Á¡À¯À²À» Â÷ÁöÇßÁö¸¸, ±× ÁÖµÈ ÀÌÀ¯´Â ÀÌ Áö¿ªÀÇ °ß°íÇÑ ÀÇ·á ÀÎÇÁ¶ó, ÃÖ÷´Ü Áø´Ü µµ±¸ÀÇ Á¶±â µµÀÔ, ÁÖ¿ä ¾÷°è ±â¾÷ÀÇ °·ÂÇÑ Á¸Àç¿´½À´Ï´Ù. ƯÈ÷ ¹Ì±¹Àº ÀǷῬ±¸¿Í Áø´Ü±â¼ú Çõ½Å¿¡ ´ëÇÑ ¸¹Àº ÅõÀÚ¸¦ ÅëÇØ °è¼Ó ¿ìÀ§¸¦ Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ¹Ý¸é ¾Æ½Ã¾ÆÅÂÆò¾çÀº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸¥ CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î Àü¸ÁµË´Ï´Ù. Áß±¹, Àεµ, ÀϺ» µîÀº ÀÇ·áºñ È®´ë, Àα¸ Áõ°¡, ¸¸¼º Áúȯ ºÎ´ã Áõ°¡, Á¤ºÎ ÁÖµµ¿¡ ÀÇÇÑ Áø´Ü ±â´ÉÀÇ ±Ù´ëÈ µîÀ¸·Î ÀÌ ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù. À¯·´Àº ¶ÇÇÑ ±¤¹üÀ§ÇÑ ½ºÅ©¸®´× ÇÁ·Î±×·¥, °í±Þ ÀÇ·á ¾×¼¼½º, Áø´Ü ½ÇÇè½Ç ¹× »ý¸í °øÇÐ ±â¾÷ °£ÀÇ Çù·Â üÁ¦¸¦ Áö¿øÇÏ¿© ¸Å¿ì Áß¿äÇÑ ½ÃÀåÀÌ µÇ¾ú½À´Ï´Ù.
ÀÌ º¸°í¼ÀÇ ¸ñÀûÀº ÃÖ±Ù ¿©·¯ ºÎ¹®¿Í ±¹°¡ ½ÃÀå ±Ô¸ð¸¦ ¹àÈ÷°í ÇâÈÄ ¸î ³â°£ ½ÃÀå ±Ô¸ð¸¦ ¿¹ÃøÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ º¸°í¼´Â ºÐ¼® ´ë»ó ±¹°¡¿¡¼ ¾÷°èÀÇ ÁúÀû ¹× ¾çÀû Ãø¸éÀ» ¸ðµÎ Æ÷ÇÔÇϵµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù. ¶ÇÇÑ ½ÃÀå Àü¸Á ¼ºÀåÀ» ±ÔÁ¤ÇÏ´Â ÃßÁø ¿äÀΰú µµÀü°ú °°Àº Áß¿äÇÑ Ãø¸é¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ ÁÖ¿ä ±â¾÷ÀÇ °æÀï ±¸µµ¿Í Á¦Ç° Á¦°ø¿¡ ´ëÇÑ »ó¼¼ÇÑ ºÐ¼®°ú ÇÔ²² ÀÌÇØ°ü°èÀÚ°¡ ÅõÀÚÇÒ ¼ö ÀÖ´Â ¸¶ÀÌÅ©·Î ½ÃÀåÀÇ ÀáÀçÀûÀÎ ±âȸµµ Æ÷ÇÔÇϰí ÀÖ½À´Ï´Ù.
The Global IVD Reagents Market is valued at approximately USD 80.72 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of more than 6.80% over the forecast period from 2025 to 2035. In-vitro diagnostic (IVD) reagents are indispensable components in medical diagnostics, enabling clinicians and laboratories to perform accurate, early, and disease-specific tests. These reagents are used in combination with IVD instruments and kits to identify infections, chronic conditions, and genetic predispositions, significantly accelerating the decision-making process for healthcare providers. The proliferation of chronic and infectious diseases, compounded by a global aging population and increasing patient awareness, is propelling the demand for sophisticated and rapid diagnostic solutions - thereby catalyzing the growth of the IVD reagents market globally.
The market's trajectory is further augmented by ongoing advancements in diagnostics technology, including automation, high-throughput testing, and miniaturization of diagnostic devices. For instance, the rising deployment of molecular diagnostic techniques during and after the COVID-19 pandemic has underscored the need for scalable and efficient reagent formulations. Additionally, the surge in personalized medicine, coupled with rising investments in genomics and biomarker research, has positioned reagents at the epicenter of innovation in healthcare diagnostics. However, the market is not without its restraints - high costs associated with sophisticated reagents and instruments, stringent regulatory frameworks, and reimbursement limitations are some of the headwinds anticipated to pose challenges to rapid expansion.
Geographically, North America held the lion's share of the global IVD reagents market in 2024, largely due to the region's robust healthcare infrastructure, early adoption of cutting-edge diagnostic tools, and strong presence of key industry players. The United States, in particular, continues to dominate due to its significant investments in healthcare research and diagnostics innovation. Meanwhile, the Asia Pacific region is expected to witness the fastest CAGR over the forecast period. Nations like China, India, and Japan are driving this growth, owing to their expanding healthcare expenditure, growing population base, increasing burden of chronic diseases, and government-led initiatives to modernize diagnostics capabilities. Europe also remains a pivotal market, supported by widespread screening programs, advanced healthcare access, and collaborative efforts among diagnostic laboratories and biotech companies.
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within the countries involved in the study. The report also provides detailed information about crucial aspects, such as driving factors and challenges, which will define the future growth of the market. Additionally, it incorporates potential opportunities in micro-markets for stakeholders to invest, along with a detailed analysis of the competitive landscape and product offerings of key players. The detailed segments and sub-segments of the market are explained below: